PCYC-1001: Factor VIIa Inhibitor Phase II Trial in Pancreatic Cancer

      To access the most up-to-date information on this study,
      please refer to this page at ClinicalTrials.gov.

Official Title

Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine.

Purpose

The purpose of this study is to evaluate the safety and tolerability of PCI-27483 administered subcutaneously (SC) twice daily in metastatic or locally advanced pancreatic cancer patients receiving concurrent therapy with intravenously administered gemcitabine for 12 weeks.

Click here for an animation of PCI-27483 effects on cell signaling.